Bio-Rad Laboratories Files Definitive Proxy Statement

Ticker: BIO-B · Form: DEF 14A · Filed: Mar 27, 2024 · CIK: 12208

Bio-Rad Laboratories, Inc. DEF 14A Filing Summary
FieldDetail
CompanyBio-Rad Laboratories, Inc. (BIO-B)
Form TypeDEF 14A
Filed DateMar 27, 2024
Risk Levellow
Pages16
Reading Time19 min
Key Dollar Amounts$300,000 B, $200,000, $100,000
Sentimentneutral

Sentiment: neutral

Topics: DEF 14A, Proxy Statement, Bio-Rad Laboratories, Executive Compensation, Corporate Governance

TL;DR

<b>Bio-Rad Laboratories, Inc. has filed its Definitive Proxy Statement for the fiscal year ending December 31, 2023.</b>

AI Summary

BIO-RAD LABORATORIES, INC. (BIO-B) filed a Proxy Statement (DEF 14A) with the SEC on March 27, 2024. Bio-Rad Laboratories, Inc. filed a Definitive Proxy Statement (DEF 14A) on March 27, 2024. The filing covers the fiscal year ending December 31, 2023. The company's principal executive offices are located at 1000 Alfred Nobel Drive, Hercules, CA 94547. The SIC code for Bio-Rad Laboratories, Inc. is 3826 (Laboratory Analytical Instruments). The filing includes data for fiscal years 2020 through 2023.

Why It Matters

For investors and stakeholders tracking BIO-RAD LABORATORIES, INC., this filing contains several important signals. This DEF 14A filing provides shareholders with information regarding the company's annual meeting, including matters to be voted upon, executive compensation details, and director nominations. Shareholders can review executive compensation data and other corporate governance information to make informed voting decisions.

Risk Assessment

Risk Level: low — BIO-RAD LABORATORIES, INC. shows low risk based on this filing. The filing is a routine DEF 14A, providing standard disclosures without immediate financial or operational news.

Analyst Insight

Review the proxy statement for details on executive compensation, director nominees, and any shareholder proposals to inform voting decisions.

Key Numbers

  • 2024-03-27 — Filing Date (DEF 14A filing date)
  • 2023-12-31 — Fiscal Year End (Reporting period)
  • 2020-01-01 — Data Start Year (Historical data included)
  • 2023-12-31 — Data End Year (Latest fiscal year data)

Key Players & Entities

  • BIO-RAD LABORATORIES, INC. (company) — Filer name
  • 0000012208 (company) — Central Index Key
  • 3826 (company) — Standard Industrial Classification
  • 1000 ALFRED NOBEL DRIVE (company) — Business Address
  • HERCULES (company) — City
  • CA (company) — State
  • 94547 (company) — ZIP Code
  • 5107247000 (company) — Business Phone

FAQ

When did BIO-RAD LABORATORIES, INC. file this DEF 14A?

BIO-RAD LABORATORIES, INC. filed this Proxy Statement (DEF 14A) with the SEC on March 27, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by BIO-RAD LABORATORIES, INC. (BIO-B).

Where can I read the original DEF 14A filing from BIO-RAD LABORATORIES, INC.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by BIO-RAD LABORATORIES, INC..

What are the key takeaways from BIO-RAD LABORATORIES, INC.'s DEF 14A?

BIO-RAD LABORATORIES, INC. filed this DEF 14A on March 27, 2024. Key takeaways: Bio-Rad Laboratories, Inc. filed a Definitive Proxy Statement (DEF 14A) on March 27, 2024.. The filing covers the fiscal year ending December 31, 2023.. The company's principal executive offices are located at 1000 Alfred Nobel Drive, Hercules, CA 94547..

Is BIO-RAD LABORATORIES, INC. a risky investment based on this filing?

Based on this DEF 14A, BIO-RAD LABORATORIES, INC. presents a relatively low-risk profile. The filing is a routine DEF 14A, providing standard disclosures without immediate financial or operational news.

What should investors do after reading BIO-RAD LABORATORIES, INC.'s DEF 14A?

Review the proxy statement for details on executive compensation, director nominees, and any shareholder proposals to inform voting decisions. The overall sentiment from this filing is neutral.

How does BIO-RAD LABORATORIES, INC. compare to its industry peers?

Bio-Rad Laboratories operates in the laboratory analytical instruments industry, providing products for research and clinical diagnostics.

Are there regulatory concerns for BIO-RAD LABORATORIES, INC.?

The DEF 14A filing is a standard requirement under the Securities Exchange Act of 1934 for public companies soliciting proxies from shareholders.

Industry Context

Bio-Rad Laboratories operates in the laboratory analytical instruments industry, providing products for research and clinical diagnostics.

Regulatory Implications

The DEF 14A filing is a standard requirement under the Securities Exchange Act of 1934 for public companies soliciting proxies from shareholders.

What Investors Should Do

  1. Review the executive compensation tables for details on CEO and other named executive officer pay.
  2. Examine the director biographies and independence status.
  3. Note any shareholder proposals and management's recommendations.

Year-Over-Year Comparison

This is the initial DEF 14A filing for the fiscal year ending December 31, 2023, following previous filings for earlier fiscal years.

Filing Stats: 4,660 words · 19 min read · ~16 pages · Grade level 12.6 · Accepted 2024-03-27 16:30:51

Key Financial Figures

  • $300,000 B — e directors, then starting in 2024, the $300,000 Board Member retention fee will be split,
  • $200,000 — ember retention fee will be split, with $200,000 payable in cash and $100,000 in equity
  • $100,000 — plit, with $200,000 payable in cash and $100,000 in equity grants of restricted stock un

Filing Documents

Election of Directors

Item 1. Election of Directors The Board of Directors recommends that you vote FOR the director nominees named below for the class or classes of Common Stock that you hold. Our Board of Directors currently has six members. The term of each of our current directors expires as of the date of the annual meeting of stockholders or on election and qualification of his or her successor. All of our current directors are standing for re-election to our Board. The Board of Directors appointed Alice N. Schwartz effective as of April 26, 2022 a Director Emeritus. A Director Emeritus has the option to attend Board meetings and receive Board materials at the discretion of the Secretary of the Company but does not have voting power and does not receive compensation. At the Annual Meeting, the stockholders will elect six directors. The six persons nominated are: Jeffrey L. Edwards, Gregory K. Hinckley, Melinda Litherland, Arnold A. Pinkston, Allison Schwartz, and Norman Schwartz. The table below includes biographies for each nominee and an indication of the class of Common Stock for which the person is a director nominee. Allison Schwartz is the daughter of Norman Schwartz. No other family relationships exist among our current and nominated directors or executive officers. The directors elected at this meeting will serve until the next annual meeting of stockholders or until their respective successors are elected and qualified. Although it is not contemplated that any nominee will decline or be unable to serve as a director, in the event that at the meeting or any adjournments or postponements thereof any nominee declines or is unable to serve, the persons named in the enclosed proxy will, in their discretion, vote the shares subject to such proxy for another person selected by the Board. DIRECTOR NOMINEES JEFFREY L. EDWARDS Former EVP, Chief Financial Officer of Allergan, Inc. Director Since: 2017 Age: 63 Class of Common Stock to Elect: Class B Mr. Edwards retired

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.